title: Efficacy and safety in sitagliptin therapy for diabetes complicated by non-alcoholic fatty liver disease.
abstract: OBJECTIVE
  The aim of this case-control study was to assess the efficacy and safety of dipeptidyl peptidase-4 inhibitor (sitagliptin) for type 2 diabetes mellitus (T2DM) with non-alcoholic fatty liver disease (NAFLD).
  
  
  METHODS
  Twenty NAFLD patients with T2DM treated by sitagliptin were retrospectively enrolled as the sitagliptin group. These patients were given sitagliptin between January 2010 and July 2011. Another 20 NAFLD patients with T2DM treated only with diet and exercise for 48 weeks were selected as the control group. Serum levels of fasting plasma glucose (FPG), hemoglobin A1C (HbA1c), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were measured before and 12, 24, 36 and 48 weeks after the initiation of treatment.
  
  
  RESULTS
  In the sitagliptin group, average HbA1c levels decreased approximately 0.7% at 48 weeks after the initiation of sitagliptin. Next, average FPG levels decreased approximately 15 mg/dL at 48 weeks after the initiation of sitagliptin. The serum levels of HbA1c and FPG in the sitagliptin group decreased with statistical significance compared to those in the control group (P < 0.05). All the patients could take sitagliptin of 50 mg/day without reduction necessitated by sitagliptin-related side-effects. There were no significant changes of average AST and ALT levels during follow up of 48 weeks in both sitagliptin and control groups.
  
  
  CONCLUSIONS
  Our results indicate sitagliptin is effective and safe for the treatment of T2DM complicated with NAFLD.
authors.affiliation: Department of Hepatology and Okinaka Memorial Institute for Medical Research, Toranomon Hospital, Tokyo, Japan; Department of Health Management Center, Toranomon Hospital, Tokyo, Japan.
authors.forename: Yasuji
authors.initials: Y
authors.lastname: Arase
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Kawamura
authors.forename: Yuya
authors.initials: Y
authors.lastname: Seko
authors.forename: Mariko
authors.initials: M
authors.lastname: Kobayashi
authors.forename: Fumitaka
authors.initials: F
authors.lastname: Suzuki
authors.forename: Yoshiyuki
authors.initials: Y
authors.lastname: Suzuki
authors.forename: Norio
authors.initials: N
authors.lastname: Akuta
authors.forename: Masahiro
authors.initials: M
authors.lastname: Kobayashi
authors.forename: Hitomi
authors.initials: H
authors.lastname: Sezaki
authors.forename: Satoshi
authors.initials: S
authors.lastname: Saito
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Hosaka
authors.forename: Kenji
authors.initials: K
authors.lastname: Ikeda
authors.forename: Hiromitsu
authors.initials: H
authors.lastname: Kumada
authors.forename: Yuki
authors.initials: Y
authors.lastname: Ohmoto-Sekine
authors.forename: Shiun Dong
authors.initials: SD
authors.lastname: Hsieh
authors.forename: Kazuhisa
authors.initials: K
authors.lastname: Amakawa
authors.forename: Kyoko
authors.initials: K
authors.lastname: Ogawa
authors.forename: Naoki
authors.initials: N
authors.lastname: Matsumoto
authors.forename: Akiko
authors.initials: A
authors.lastname: Iwao
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Tsuji
authors.forename: Shigeko
authors.initials: S
authors.lastname: Hara
authors.forename: Yasumichi
authors.initials: Y
authors.lastname: Mori
authors.forename: Minoru
authors.initials: M
authors.lastname: Okubo
authors.forename: Hirohito
authors.initials: H
authors.lastname: Sone
authors.forename: Tetsuro
authors.initials: T
authors.lastname: Kobayashi
keywords: non-alcoholic fatty liver disease; sitagliptin; type 2 diabetes mellitus